Methods for surveillance of antimalarial drug efficacy.
Publication details: Geneva : World Health Organization, 2009. Description: 85 p. : illISBN: 9789241597531Subject(s): Epidemiologic surveillance | Antimalarials | Drug resistance | Plasmodium | Malaria | Drug evaluation | Epidemiologic research designNLM classification: QV 256 M 2009Summary: Routine monitoring of antimalarial drug efficacy is necessary to ensure effective case management and for early detection of resistance. WHO recommends that the efficacy of first- and second-line antimalarial treatments be tested at least once every 24 months at all sentinel sites. Data collected from studies conducted according to the standard protocol inform national treatment policies. This document includes tools and materials to conduct routine therapeutic efficacy studies (TES). It is a reference for national programmes and investigators conducting routine surveillance studies to assess the efficacy of medicines that have already been registered.Item type | Current library | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|
WHO Publications | FNPH LIBRARY | QV 256 M 2009 (Browse shelf(Opens below)) | Available | 02844 |
Browsing FNPH LIBRARY shelves Close shelf browser (Hides shelf browser)
No cover image available | ||||||||
QV 256 G 2010 Global report on antimalarial drug efficacy and drug resistance. | QV 256 G 2011 Global plan for artemisinin resistance containment. | QV 256 G 2011 Executive summary : | QV 256 M 2009 Methods for surveillance of antimalarial drug efficacy. | QV 256 U 2001 The use of antimalarial drugs : | QV 268.5 S 2002 Scaling up antiretroviral therapy in resource-limited settings : | QV 275 B 2001 Beryllium and beryllium compounds. |
Routine monitoring of antimalarial drug efficacy is necessary to ensure effective case management and for early detection of resistance. WHO recommends that the efficacy of first- and second-line antimalarial treatments be tested at least once every 24 months at all sentinel sites. Data collected from studies conducted according to the standard protocol inform national treatment policies.
This document includes tools and materials to conduct routine therapeutic efficacy studies (TES). It is a reference for national programmes and investigators conducting routine surveillance studies to assess the efficacy of medicines that have already been registered.
There are no comments on this title.